# Contact Peptide Batteries — Editorial Desk

> Reach the Peptide Batteries editorial desk regarding citations, corrections, or research-related correspondence about our Research Peptide Fundamentals digest.

Correspondence on citations, corrections, and research-related inquiries — the things a reference desk is most useful to hear about.

## Editorial correspondence

Peptide Batteries welcomes correspondence on the research record: a citation quoted inaccurately, a newly published trial result, a regulatory status change, or a peer-reviewed study on GHK-Cu, MOTS-c, retatrutide, or tirzepatide that should be added to the references page. This is the most useful class of message this desk receives, and each one is read carefully.

The most actionable submissions specify the page in question, the exact passage being corrected, and a supporting reference — a DOI or PubMed identifier wherever possible — so the proposed change can be checked against its source before anything is updated.

Editorial mailbox: editors@peptidebatteries.com

## What this desk cannot do

As a literature digest rather than a clinical service, this desk cannot advise on or recommend human use of any peptide discussed here, suggest a dose or administration schedule for any individual, evaluate whether a cited trial result applies to a specific person's situation, or help source, sell, or locate any compound from any supplier. Tirzepatide is a prescription medicine available only through a licensed provider. Retatrutide is investigational and not legally available outside a registered clinical trial. GHK-Cu's approved use is topical and cosmetic. MOTS-c has no approved human use. Readers seeking clinical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed.

---

A data-forward digest of peptide research — effect sizes and study designs, reported as measured, never as a prescription.